What’s Next for Neurocrine Biosciences, Inc. (NBIX) After Reaching 52-Week High?

June 13, 2018 - By Migdalia James

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Logo

Investors sentiment decreased to 1.16 in 2018 Q1. Its down 0.15, from 1.31 in 2017Q4. It turned negative, as 22 investors sold Neurocrine Biosciences, Inc. shares while 79 reduced holdings. 36 funds opened positions while 81 raised stakes. 89.67 million shares or 1.73% less from 91.25 million shares in 2017Q4 were reported.
Woodstock holds 16,578 shares or 0.26% of its portfolio. Northwestern Mutual Wealth Mgmt has 111 shares. Tocqueville Asset Mgmt Ltd Partnership reported 17,575 shares. M&T State Bank Corp holds 2,826 shares or 0% of its portfolio. Eam Invsts Ltd Co owns 0.57% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 41,529 shares. Jennison Associate Ltd invested in 0.03% or 392,535 shares. Wells Fargo Mn accumulated 955,308 shares. Bb Biotech Ag holds 3.40M shares or 7.8% of its portfolio. Delaware-based Dupont Capital Corporation has invested 0.02% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). 2,524 were reported by Manufacturers Life Insur The. Point72 Asset Lp stated it has 0.03% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). State Of Wisconsin Inv Board accumulated 0% or 17,765 shares. Brown Brothers Harriman And Com has 0% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Arrowmark Colorado Hldgs Limited Liability Co has invested 0.62% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Stratos Wealth Ptnrs Ltd owns 20 shares.

Since January 2, 2018, it had 0 buys, and 25 sales for $41.45 million activity. 1,625 shares were sold by Bozigian Haig P., worth $128,575. 1,625 shares valued at $128,563 were sold by Grigoriadis Dimitri E. on Tuesday, January 16. GORMAN KEVIN CHARLES sold $10.24M worth of stock. 1,750 shares were sold by OBrien Christopher Flint, worth $138,499 on Tuesday, January 16. 5,000 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares with value of $415,380 were sold by LYONS GARY A. Gano Kyle sold $2.13 million worth of stock.

The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) hit a new 52-week high and has $101.69 target or 3.00 % above today’s $98.73 share price. The 5 months bullish chart indicates low risk for the $8.88 billion company. The 1-year high was reported on Jun, 13 by Barchart.com. If the $101.69 price target is reached, the company will be worth $266.28 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 2.32% or $2.34 during the last trading session, reaching $98.73. About 311,795 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 93.65% since June 13, 2017 and is uptrending. It has outperformed by 81.08% the S&P500.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on August, 2. They expect $-0.18 earnings per share, up 73.53 % or $0.50 from last year’s $-0.68 per share. After $-0.47 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -61.70 % EPS growth.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 10 analysts covering Neurocrine (NASDAQ:NBIX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine had 19 analyst reports since January 8, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, January 25 by Piper Jaffray. Oppenheimer maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Thursday, February 22. Oppenheimer has “Buy” rating and $110.0 target. The company was maintained on Wednesday, February 14 by Oppenheimer. Deutsche Bank maintained the stock with “Buy” rating in Tuesday, May 1 report. The stock has “Buy” rating by Piper Jaffray on Monday, January 8. The firm earned “Overweight” rating on Wednesday, February 14 by JP Morgan. H.C. Wainwright maintained it with “Buy” rating and $13900 target in Tuesday, May 1 report. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Oppenheimer on Monday, January 15. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, February 14. JP Morgan maintained the shares of NBIX in report on Tuesday, May 1 with “Overweight” rating.

Another recent and important Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” on June 01, 2018.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $8.88 billion. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.